Jul 11, 2025 / 12:00PM GMT
Christoffer Rosenblad - Xvivo Perfusion AB - Chief Executive Officer
Thank you so much, and good morning and good afternoon, and welcome to XVIVO's earnings call for the second quarter of 2025.
I go to the first page after the front page. So today's presenters are me, Christoffer Rosenblad, CEO of XVIVO; and Kristoffer Nordstrom, CFO. And with that, we go to Slide 2, the Q2 finance at the glance. I am disappointed to report that Q2 shows negative top line growth compared to the same quarter last year. The three main reasons are a slower-than-expected lung market that led to some destocking, lack of heart sales compared to both expectations and last year and thirdly, a weaker US dollar.
The positive news, however, in the quarter, two are that where we invest in field force. We see strong growth and a positive momentum. For example, the US lung sales to clinic and OPOs grew by 26%. Liver in Europe grew by 32% and kidney sales in the US grew by 47% during the second quarter of this year.
The quarter also showed great progress in terms of milestones for future growth. The key event
Q2 2025 Xvivo Perfusion AB Earnings Call Transcript
Jul 11, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers